2. Academic Validation
  3. HIV co-receptor inhibitors as novel class of anti-HIV drugs

HIV co-receptor inhibitors as novel class of anti-HIV drugs

  • Antiviral Res. 2006 Sep;71(2-3):216-26. doi: 10.1016/j.antiviral.2006.04.009.
Dominique Schols 1
Affiliations

Affiliation

  • 1 Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Dominique.schols@rega.kuleuven.be
PMID: 16753228 DOI: 10.1016/j.antiviral.2006.04.009
Abstract

Entry inhibitors constitute a new class of drugs to treat Infection by human immunodeficiency virus type 1 (HIV-1). The first member of this class, enfuvirtide, previously known as T-20 and targeting gp41, has now been licensed for therapeutic use. Several other entry inhibitors are in various stages of pre-clinical or clinical development. In this review we focus on the Chemokine Receptor inhibitors targeting CCR5 and CXCR4 that are the main HIV co-receptors for viral entry.

Figures
Products